SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

28 Aug 2024 03:30:35 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

07 Aug 2024 03:30:35 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

29 Jul 2024 03:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

23 Jul 2024 04:00:02 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

01 Jul 2024 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 04:00:52 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 14:13:28 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

08 May 2024 04:00:27 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

02 May 2024 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 10:31:32 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

18 Apr 2024 04:00:28 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

04 Mar 2024 03:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

29 Feb 2024 05:30:13 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

27 Feb 2024 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

22 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 Jan 2024 04:00:50 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

08 Jan 2024 03:30:44 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023 04:00:25 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

08 Dec 2023 13:05:10 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

04 Dec 2023 21:32:11 By Nasdaq GlobeNewswire